DataVXACS NanoPaper
journal article·2019-10-22Open access

Multilamellar Vaccine Particle Elicits Potent Immune Activation with Protein Antigens and Protects Mice against Ebola Virus Infection

Yuchen Fan, Sabrina M. Stronsky, Yao Xu, Jesse T. Steffens, Sean A. van Tongeren, Amanda Erwin, Christopher L. Cooper, James J. Moon

ACS Nano· Volume 13· Issue 10
Publisher pageOpen full text
Source abstract

Abstract

Recent outbreaks of emerging infectious diseases, such as Ebola virus disease (EVD), highlight the urgent need to develop effective countermeasures, including prophylactic vaccines. Subunit proteins derived from pathogens provide a safe source of antigens for vaccination, but they are often limited by their low immunogenicity. We have developed a multilamellar vaccine particle (MVP) system composed of lipid–hyaluronic acid multi-cross-linked hybrid nanoparticles for vaccination with protein antigens and demonstrate their efficacy against Ebola virus (EBOV) exposure. MVPs efficiently accumulated in dendritic cells and promote antigen processing. Mice immunized with MVPs elicited robust and long-lasting antigen-specific CD8+ and CD4+ T cell immune responses as well as humoral immunity. A single-dose vaccination with MVPs delivering EBOV glycoprotein achieved an 80% protection rate against lethal EBOV infection. These results suggest that MVPs offer a promising platform for improving recombinant protein-based vaccine approaches.
Source: openalex_inverted_index · Quality: baseline

Research context

Nanomaterials

OpenAlex topics: Viral Infections and Outbreaks Research · SARS-CoV-2 and COVID-19 Research · COVID-19 epidemiological studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, Michigan 48109, United States

Biointerfaces Institute, University of Michigan, Ann Arbor, Michigan 48109, United States

Molecular and Translational Sciences, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Maryland 21702, United States

Joint Program Executive Office - Chemical, Biological, Radiological, and Nuclear Defense (JPEO−CBRND), Fort Detrick, Maryland 21702, United States

Department of Cell and Developmental Biology, University of Michigan, Ann Arbor, Michigan 48109, United States

Department of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan 48109, United States

Funding

University of Michigan · National Cancer Institute · Melanoma Research Alliance · National Institute of Allergy and Infectious Diseases · National Institute of Biomedical Imaging and Bioengineering · U.S. Department of Defense · Defense Threat Reduction Agency · Division of Chemical, Bioengineering, Environmental, and Transport Systems · Emerald Foundation

References (42)

Show source-provided references
1. 10.1016/S2214-109X(15)00092-310.1016/S2214-109X(15)00092-3 ↗
2. 10.1016/S1473-3099(16)30332-210.1016/S1473-3099(16)30332-2 ↗
3. 10.1038/nrmicro287210.1038/nrmicro2872 ↗
4. 10.1016/S0140-6736(16)32621-610.1016/S0140-6736(16)32621-6 ↗
5. 10.1056/NEJMoa150292410.1056/NEJMoa1502924 ↗
6. 10.1056/NEJMoa141421610.1056/NEJMoa1414216 ↗
7. 10.3390/vaccines203062410.3390/vaccines2030624 ↗
8. 10.1099/jgv.0.00108510.1099/jgv.0.001085 ↗
9. 10.1016/j.celrep.2019.01.06910.1016/j.celrep.2019.01.069 ↗
10. 10.1021/acs.chemrev.5b0010910.1021/acs.chemrev.5b00109 ↗
11. 10.3390/vaccines303066210.3390/vaccines3030662 ↗
12. 10.1002/wnan.140310.1002/wnan.1403 ↗
13. 10.1038/nmat296010.1038/nmat2960 ↗
14. 10.1073/pnas.111264810910.1073/pnas.1112648109 ↗
15. 10.1126/scitranslmed.300651610.1126/scitranslmed.3006516 ↗
16. 10.1016/j.nano.2018.11.00510.1016/j.nano.2018.11.005 ↗
17. 10.1021/acs.nanolett.8b0360110.1021/acs.nanolett.8b03601 ↗
18. 10.1016/j.jconrel.2015.04.01010.1016/j.jconrel.2015.04.010 ↗
19. 10.1055/s-0029-122064710.1055/s-0029-1220647 ↗
20. 10.1189/jlb.101250110.1189/jlb.1012501 ↗
21. 10.4161/onci.2093110.4161/onci.20931 ↗
22. 10.1186/s12014-016-9119-810.1186/s12014-016-9119-8 ↗
23. 10.1002/biot.20170062710.1002/biot.201700627 ↗
24. 10.1016/j.vaccine.2016.02.03310.1016/j.vaccine.2016.02.033 ↗
25. 10.1089/vim.2014.007110.1089/vim.2014.0071 ↗
26. 10.1529/biophysj.104.04036010.1529/biophysj.104.040360 ↗
27. 10.1016/j.virol.2010.02.02910.1016/j.virol.2010.02.029 ↗
28. 10.1126/science.287.5458.166410.1126/science.287.5458.1664 ↗
29. 10.1016/j.it.2016.10.00310.1016/j.it.2016.10.003 ↗
30. 10.1146/annurev-immunol-032712-09591010.1146/annurev-immunol-032712-095910 ↗
31. 10.2147/IJN.S12586610.2147/IJN.S125866 ↗
32. 10.1016/j.vaccine.2011.01.11310.1016/j.vaccine.2011.01.113 ↗
33. 10.1371/journal.pone.016244610.1371/journal.pone.0162446 ↗
34. 10.1016/j.vaccine.2017.01.06810.1016/j.vaccine.2017.01.068 ↗
35. 10.1073/pnas.120959111010.1073/pnas.1209591110 ↗
36. 10.1016/j.ebiom.2015.11.04110.1016/j.ebiom.2015.11.041 ↗
37. 10.1155/2011/98424110.1155/2011/984241 ↗
38. 10.1126/scitranslmed.300458210.1126/scitranslmed.3004582 ↗
39. 10.1038/emi.2017.3110.1038/emi.2017.31 ↗
40. 10.1021/acs.nanolett.7b0321810.1021/acs.nanolett.7b03218 ↗
41. 10.1016/S0022-1759(98)00204-X10.1016/S0022-1759(98)00204-X ↗
42. 10.3791/5277110.3791/52771 ↗